Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire private biotech Proteologix for $850 million in cash, with the potential for an additional milestone payment. The transaction is expected to be closed in mid-2024, subject to customary closing conditions. With the latest acquisition, JNJ is looking to boost its dermatology portfolio with an aim to address significant unmet needs in atopic dermatitis (AD), also known as eczema. Proteologix is engaged in developing bi ...